Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer

Fig. 2

Progression-free survival (A) and overall survival outcomes. Kaplan-Meier analysis of survival showing progression-free survival (A) and overall survival (C) in cohort 1, and progression-free survival (B) and overall survival (D) in cohort 2. Kaplan-Meier estimates of progression-free survival by Response Evaluation Criteria in Solid Tumors version 1.1. HR = hazard ratio

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us